Hereditary Haemochromatosis

What is Hereditary Haemochromatosis?

Hereditary haemochromatosis is a genetic disorder that causes the body to absorb too much iron from food, leading to iron overload in organs and tissues. This condition primarily affects people of Northern European descent and is one of the most common genetic disorders in populations of Celtic origin. The excess iron accumulates over time in vital organs including the liver, heart, pancreas, and joints, potentially causing serious health complications if left untreated. Early diagnosis and treatment are crucial for preventing irreversible organ damage and maintaining normal life expectancy.

Key statistics

Symptoms

Early symptoms include fatigue, weakness, joint pain, abdominal pain, and loss of sex drive. Many people experience no symptoms in the early stages, earning haemochromatosis the nickname “the silent killer.”

Early symptoms: Chronic fatigue is often the first sign, accompanied by general weakness and lethargy that doesn’t improve with rest. Joint pain, particularly in the knuckles and wrists, may develop gradually. Abdominal discomfort and unexplained weight loss can also occur.

Progressive symptoms: As iron accumulates, patients may develop bronze or gray skin pigmentation, giving a characteristic metallic appearance. Liver enlargement becomes apparent, often accompanied by tenderness in the upper right abdomen. Men may experience erectile dysfunction and loss of body hair, while women may have irregular menstrual periods.

Submit Your Paper

Advanced symptoms: Severe complications include diabetes mellitus due to pancreatic iron deposits, heart problems including irregular heartbeat and heart failure, severe arthritis affecting multiple joints, and cirrhosis with potential liver failure. Some patients develop severe depression and cognitive difficulties.

Causes and risk factors

Hereditary haemochromatosis is caused by mutations in genes that regulate iron absorption, most commonly the HFE gene located on chromosome 6. The C282Y mutation accounts for approximately 85% of cases, while the H63D mutation is associated with milder forms of the condition. These genetic defects disrupt the normal production of hepcidin, a hormone that controls iron absorption in the intestines.

Risk factors include: Northern European ancestry, particularly Celtic, Germanic, or Scandinavian heritage; family history of haemochromatosis, liver disease, or diabetes; being male (symptoms typically appear earlier due to lack of menstrual iron loss); and having two copies of the disease-causing gene mutations. Environmental factors such as high iron intake, alcohol consumption, and vitamin C supplementation can accelerate iron accumulation in genetically predisposed individuals.

Prevention

Currently, there is no known way to prevent hereditary haemochromatosis as it is an inherited genetic condition. However, early detection through genetic screening and carrier testing can help families make informed decisions about family planning and enable early intervention. Cascade screening of family members is recommended when a case is identified. Individuals with known genetic risk can benefit from regular monitoring of iron levels and early treatment before symptoms develop. Avoiding unnecessary iron supplementation and limiting alcohol consumption may help slow iron accumulation in at-risk individuals.

Complications

Without treatment, hereditary haemochromatosis can lead to life-threatening complications. Liver complications include cirrhosis, liver failure, and significantly increased risk of hepatocellular carcinoma (liver cancer), which can occur even after successful iron depletion. Cardiac complications encompass cardiomyopathy, irregular heart rhythms, and congestive heart failure.

Endocrine complications include diabetes mellitus (bronze diabetes), hypogonadism leading to infertility and sexual dysfunction, and thyroid disorders. The musculoskeletal system may develop severe arthropathy, particularly affecting the hands, wrists, and knees, which may not improve even with iron depletion. Skin pigmentation changes are often permanent, and some patients experience increased susceptibility to certain bacterial infections due to iron’s role in bacterial growth.

Diagnosis

Diagnosis begins with blood tests measuring serum iron, transferrin saturation, and serum ferritin levels. A transferrin saturation above 45% or elevated ferritin levels warrant further investigation. Genetic testing for HFE gene mutations (C282Y, H63D, and S65C) confirms the diagnosis and determines the specific type of haemochromatosis.

Additional tests include a complete blood count to rule out other causes of iron overload, liver function tests, and assessment for diabetes and heart problems. Magnetic resonance imaging (MRI) of the liver can quantify iron deposits and assess for cirrhosis. In some cases, a liver biopsy may be necessary to evaluate iron content and degree of liver damage, though this is less commonly required with modern imaging techniques. Family screening is recommended once a diagnosis is confirmed.

Treatment

The primary treatment for hereditary haemochromatosis is phlebotomy (therapeutic blood removal), which is highly effective and well-tolerated. Initial treatment involves weekly phlebotomy sessions removing 450-500ml of blood until iron levels normalize, typically requiring 6-24 months. Maintenance therapy consists of periodic phlebotomy every 2-4 months to prevent iron reaccumulation.

For patients who cannot tolerate phlebotomy, iron chelation therapy with deferasirox or deferoxamine may be used. Supportive treatments address complications: diabetes management with standard antidiabetic medications, heart failure treatment with appropriate cardiac medications, and hormone replacement therapy for hypogonadism.

Dietary modifications include avoiding iron supplements, limiting vitamin C supplementation (which enhances iron absorption), and moderating alcohol consumption. Patients should avoid eating raw shellfish due to increased infection risk.

Prognosis

With early diagnosis and appropriate treatment, individuals with hereditary haemochromatosis can have a normal life expectancy and quality of life. Phlebotomy therapy is highly effective at preventing progression of iron-related organ damage when started before significant complications develop.

However, certain complications may be irreversible. Liver cirrhosis and arthropathy typically do not improve with iron depletion, though progression can be halted. Patients with cirrhosis face ongoing risks of liver cancer and liver failure. Diabetes and heart problems may improve partially with treatment. The key to optimal outcomes is early detection and treatment initiation before irreversible organ damage occurs.

Quality of life

Living with hereditary haemochromatosis requires ongoing medical management but allows for a largely normal lifestyle with proper treatment. Regular phlebotomy appointments become part of routine care, similar to other chronic conditions requiring periodic monitoring.

Dietary awareness is important: patients should read food labels to avoid iron-fortified products, limit red meat consumption, and avoid iron supplements. Tea and coffee with meals can help reduce iron absorption. Regular exercise is beneficial and generally well-tolerated once iron levels are controlled.

Mental health support may be needed, as chronic fatigue and the diagnosis of a genetic condition can impact emotional well-being. Support groups and counseling can help patients cope with lifestyle adjustments. Work accommodations may be necessary during initial treatment phases when frequent medical appointments are required.

Pregnancy and fertility

Hereditary haemochromatosis can affect fertility in both men and women due to iron accumulation in reproductive organs. Women may experience irregular menstruation or early menopause, while men may have reduced testosterone levels and fertility issues.

During pregnancy, iron requirements increase, which may actually be beneficial for women with haemochromatosis by naturally reducing iron levels. Phlebotomy can be safely continued during pregnancy if needed. Genetic counseling is strongly recommended for affected individuals and their partners to understand inheritance risks and testing options for children.

Preconception counseling should address the 25% risk of passing the condition to children when one parent is affected and the partner is a carrier. Partner testing and family planning discussions are important considerations.

Children

Hereditary haemochromatosis rarely causes symptoms in children, as iron accumulation typically requires decades to reach harmful levels. However, genetic testing can identify affected children early, allowing for monitoring and eventual early intervention.

Children of affected parents should undergo genetic testing and, if positive, have periodic monitoring of iron levels starting in adolescence. Iron supplementation should be avoided unless specifically indicated for iron deficiency anemia. Education about the condition helps families understand the importance of long-term monitoring and future treatment needs.

Transition to adult care typically occurs around age 18, with emphasis on understanding the condition and taking responsibility for ongoing monitoring and treatment.

When to see a doctor

Seek immediate medical attention for symptoms of severe complications: severe abdominal pain, yellowing of skin or eyes (jaundice), severe shortness of breath, chest pain, or irregular heartbeat. These may indicate liver failure, heart problems, or other serious complications.

Routine medical consultation is warranted for persistent fatigue, joint pain, abdominal discomfort, skin color changes, or sexual dysfunction, especially in individuals with family history of haemochromatosis or Northern European ancestry. Annual screening may be appropriate for first-degree relatives of affected individuals.

Regional context

GMJ welcomes contributions from regional researchers to build the evidence base for hereditary haemochromatosis in the Caucasus. While this condition is most prevalent in Northern European populations, genetic diversity in the Caucasus region may include individuals with relevant ancestry or novel genetic variants affecting iron metabolism.

Research and clinical trials

Current research focuses on developing new iron chelation therapies, understanding genetic modifiers that influence disease severity, and investigating the role of hepcidin replacement therapy. Studies are exploring the relationship between haemochromatosis and other conditions such as metabolic syndrome and neurodegenerative diseases.

Clinical trials are investigating novel treatments including hepcidin agonists and improved iron chelation medications. Research into genetic testing strategies and population screening approaches continues to evolve. Patients interested in clinical trials can search ClinicalTrials.gov for current opportunities.

Frequently asked questions

Is hereditary haemochromatosis curable?

While not curable, hereditary haemochromatosis is highly treatable with phlebotomy therapy. Early treatment can prevent complications and allow for normal life expectancy.

How often will I need blood removal treatments?

Initial treatment typically requires weekly phlebotomy for 6-24 months, followed by maintenance treatments every 2-4 months for life.

Can I donate my blood during phlebotomy treatment?

In many countries, blood removed during therapeutic phlebotomy can be used for transfusion if it meets safety standards, making treatment beneficial for both patient and blood supply.

Will my children definitely have this condition?

Children have a 50% chance of inheriting one copy of the gene mutation. They will only develop the condition if they inherit mutations from both parents.

Can I still drink alcohol with haemochromatosis?

Moderate alcohol consumption may be acceptable once iron levels are controlled, but alcohol should be limited as it can accelerate liver damage in the presence of iron overload.

Support and resources

International organizations providing support include the Iron Disorders Institute (www.irondisorders.org), Haemochromatosis UK (www.haemochromatosis.org.uk), and the American Hemochromatosis Society (www.americanhs.org). Orphanet (www.orpha.net) provides comprehensive information about rare diseases including haemochromatosis.

The European Rare Diseases Organisation (EURORDIS) at www.eurordis.org offers resources for rare disease patients and families. National genetic counseling services can provide family-specific guidance about inheritance and testing options.

Related conditions

Wilson disease – Another genetic disorder causing metal accumulation, but involving copper rather than iron. Secondary iron overload – Iron accumulation due to repeated blood transfusions or other medical treatments. Porphyria cutanea tarda – A condition that can be triggered by iron overload and may coexist with haemochromatosis. Alpha-1 antitrypsin deficiency – Another genetic condition that can cause liver disease and may be confused with haemochromatosis. Non-alcoholic fatty liver disease – A liver condition that may have overlapping symptoms with haemochromatosis.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Licensed under CC BY 4.0. Free to share with attribution to GMJ News.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.